The Keynote-001 trial (110) explored the clinical efficacy of PD-1 inhibitors in patients with NSCLC and found a higher incidence of any-grade CIP in patients who received RT before ICI therapy (pembrolizumab, 13%) compared with those who did not receive RT (1%, P<0.05). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.